Tenaya Therapeutics
TNYA
50 hedge funds and large institutions have $209M invested in Tenaya Therapeutics in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 21 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
0% more funds holding
Funds holding: 50 → 50 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.74% less ownership
Funds ownership: 90.46% → 89.72% (-0.74%)
48% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 21
53% less capital invested
Capital invested by funds: $440M → $209M (-$231M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.71M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$1.32M |
| 3 |
State Street
Boston,
Massachusetts
|
+$769K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$396K |
| 5 |
BlackRock
New York
|
+$276K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.36M |
| 2 |
CC
Commodore Capital
New York
|
-$1.26M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$510K |
| 4 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
-$221K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$219K |
TNYA Hedge Fund Activity: Q2 2022 in Review
50 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Tenaya Therapeutics (TNYA) for Q2 2022, worth a combined $209M — down 53% from $440M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TNYA positions and 5 closed out — a net gain of 1 holder — while 11 added to existing stakes and 21 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $2.71M. The largest seller was Fidelity Investments, cutting an estimated $5.36M.
- 50 institutional investors held Tenaya Therapeutics (TNYA) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $209M of Tenaya Therapeutics stock for Q2 2022, down 53% quarter-over-quarter.
- 6 funds opened new Tenaya Therapeutics positions in Q2 2022 and 5 closed out, a net change of +1 holder.
- The largest Tenaya Therapeutics buyer in Q2 2022 was T. Rowe Price Associates, an estimated $2.71M added.
- The largest Tenaya Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $5.36M sold.
Based on aggregated 13F filings for Q2 2022.